Etanercept. Immunex.

Pugsley, M K

Pugsley, M K.

Affiliation

Pugsley MK; Department of Pharmacology, Xoma (US) LLC, Berkeley, CA 94710, USA. PUGSLEY@xoma.com

Curr Opin Investig Drugs ; 2(12): 1725-31, 2001 Dec.

Article in En | MEDLINE | ID: mdl-11892935

Subject(s)

Antirheumatic Agents/therapeutic use; Arthritis, Rheumatoid/drug therapy; Immunoglobulin G/therapeutic use; Receptors, Tumor Necrosis Factor/therapeutic use; Recombinant Fusion Proteins/adverse effects; Animals; Antirheumatic Agents/adverse effects; Antirheumatic Agents/metabolism; Antirheumatic Agents/pharmacology; Antirheumatic Agents/toxicity; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Etanercept; Humans; Immunoglobulin G/adverse effects; Immunoglobulin G/metabolism; Immunoglobulin G/pharmacology; Immunoglobulin G/toxicity; Receptors, Tumor Necrosis Factor/metabolism; Recombinant Fusion Proteins/chemical synthesis; Recombinant Fusion Proteins/metabolism; Recombinant Fusion Proteins/pharmacology; Recombinant Fusion Proteins/therapeutic use; Recombinant Fusion Proteins/toxicity; Structure-Activity Relationship

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Recombinant Fusion Proteins / Immunoglobulin G / Receptors, Tumor Necrosis Factor / Antirheumatic Agents Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Curr Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2001 Document type: Article Affiliation country: United States Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links